Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) — Net Asset Quality Index
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has a Net Asset Quality Index of 94.2% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥6.02 Billion minus total liabilities of CN¥347.84 Million yields net assets of CN¥5.67 Billion. A higher index indicates a stronger, lower-leverage balance sheet. For live market cap and overall valuation, see 002932 company net worth.
Quality Index
Net Assets
Total Assets
Total Liabilities
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Net Asset Quality Index Over Time (2011–2025)
This chart shows how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the index stands at 94.2%, representing net assets of CN¥5.67 Billion against total assets of CN¥6.02 Billion CNY. See 002932 total equity for net asset value and shareholders' equity analysis.
Annual Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below presents the year-by-year Net Asset Quality Index for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check 002932 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 94.6% | CN¥5.66 Billion | CN¥5.98 Billion | CN¥324.56 Million | ▲ +3.3 pp |
| 2024 | 91.3% | CN¥6.02 Billion | CN¥6.59 Billion | CN¥574.40 Million | ▲ +6.1 pp |
| 2023 | 85.2% | CN¥6.29 Billion | CN¥7.39 Billion | CN¥1.09 Billion | ▲ +11.5 pp |
| 2022 | 73.7% | CN¥6.77 Billion | CN¥9.19 Billion | CN¥2.42 Billion | ▼ -9.7 pp |
| 2021 | 83.4% | CN¥2.85 Billion | CN¥3.42 Billion | CN¥567.02 Million | ▲ +5.3 pp |
| 2020 | 78.1% | CN¥1.11 Billion | CN¥1.43 Billion | CN¥311.77 Million | ▼ -18.3 pp |
| 2019 | 96.4% | CN¥615.62 Million | CN¥638.42 Million | CN¥22.80 Million | ▲ +0.4 pp |
| 2018 | 96.0% | CN¥592.59 Million | CN¥617.15 Million | CN¥24.55 Million | ▲ +1.3 pp |
| 2017 | 94.7% | CN¥242.93 Million | CN¥256.54 Million | CN¥13.60 Million | ▲ +5.9 pp |
| 2016 | 88.8% | CN¥175.08 Million | CN¥197.15 Million | CN¥22.07 Million | ▲ +2.7 pp |
| 2015 | 86.1% | CN¥115.39 Million | CN¥133.96 Million | CN¥18.57 Million | ▲ +4.9 pp |
| 2014 | 81.3% | CN¥49.59 Million | CN¥61.01 Million | CN¥11.42 Million | ▲ +24.1 pp |
| 2013 | 57.1% | CN¥13.60 Million | CN¥23.79 Million | CN¥10.19 Million | ▲ +26.6 pp |
| 2012 | 30.6% | CN¥1.42 Million | CN¥4.66 Million | CN¥3.23 Million | ▲ +29.5 pp |
| 2011 | 1.1% | CN¥21.45K | CN¥1.96 Million | CN¥1.94 Million | — |